(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 June 2023 (29.06.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/120742 A1

(51) International Patent Classification:
A61K 31/517 (2006.01) *A61P 11/00* (2006.01)
A61P 1/00 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/JP2022/048717

(22) International Filing Date:
23 December 2022 (23.12.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/JP2021/049036
24 December 2021 (24.12.2021) JP

(71) Applicant: **ASTELLAS PHARMA INC.** [JP/JP]; 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411 (JP).

(72) Inventor: **NAGASHIMA, Takeyuki**; c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411 (JP).

(74) Agent: **YAMAMOTO, Osamu** et al.; Yuasa and Hara, Section 206, Shin-Otemachi Bldg., 2-1, Otemachi 2-chome, Chiyoda-ku, Tokyo 1000004 (JP).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2023/120742 A1

(54) Title: PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND

(57) Abstract: The present invention has an object to provide a pharmaceutical composition for treating a cancer of colorectal cancer and/or lung cancer. The present inventors have studied about a compound that is useful as an active ingredient of a pharmaceutical composition for treating a cancer, and have found that a quinazoline compound has an excellent degradation- inducing action on a G12D mutant KRAS protein and a G12D mutant KRAS inhibition activity and that a pharmaceutical composition containing the compound as an active ingredient can be used as a therapeutic agent for a cancer, completing the present invention. The pharmaceutical composition of the present invention which contains a quinazoline compound or a salt thereof as an active ingredient can be used as a therapeutic agent for a cancer of colorectal cancer and/or lung cancer.